APGE

SEC source: 0001104659-25-117036 · tm2532308-1_4seq1.xml · nonDerivative · entry 1

Henderson Jane · CIK 0001422304 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 196,371

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 27, 2024.

SEC source: 0001104659-25-112825 · tm2531402-1_4seq1.xml · nonDerivative · entry 1

Henderson Jane · CIK 0001422304 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 197,871

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 27, 2024.

SEC source: 0001104659-25-111626 · tm2531267-1_4seq1.xml · nonDerivative · entry 4

HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,272,987

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025.

SEC source: 0001104659-25-111626 · tm2531267-1_4seq1.xml · nonDerivative · entry 3

HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,273,087

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025.

F4 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.52 to $64.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001104659-25-111626 · tm2531267-1_4seq1.xml · nonDerivative · entry 2

HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,274,873

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025.

F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.50 to $63.47, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001104659-25-111626 · tm2531267-1_4seq1.xml · nonDerivative · entry 1

HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,289,647

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2025.

F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $61.45 to $62.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001104659-25-111631 · tm2531086-1_4seq1.xml · nonDerivative · entry 1

Henderson Jane · CIK 0001422304 · Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 199,871

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 27, 2024.

SEC source: 0001104659-25-108652 · tm2530515-1_4seq1.xml · derivative · entry 6

Dambkowski Carl · CIK 0001983476 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 153,565

Underlying: Common Stock · 8,060 shares

Expires 2033-12-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer.

SEC source: 0001104659-25-108652 · tm2530515-1_4seq1.xml · nonDerivative · entry 5

Dambkowski Carl · CIK 0001983476 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 282,008

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024.

F5 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $56.31 to $56.68, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001104659-25-108652 · tm2530515-1_4seq1.xml · nonDerivative · entry 4

Dambkowski Carl · CIK 0001983476 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 282,686

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024.

F4 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $55.25 to $56.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001104659-25-108652 · tm2530515-1_4seq1.xml · nonDerivative · entry 3

Dambkowski Carl · CIK 0001983476 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 288,293

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024.

F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $54.24 to $55.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001104659-25-108652 · tm2530515-1_4seq1.xml · nonDerivative · entry 2

Dambkowski Carl · CIK 0001983476 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 290,493

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024.

F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $53.16 to $53.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001104659-25-108652 · tm2530515-1_4seq1.xml · nonDerivative · entry 1

Dambkowski Carl · CIK 0001983476 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 292,793

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001698082-25-000003 · form4-10152025_041001.xml · derivative · entry 1

Shah Nimish P · CIK 0001698082 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 365,853

Underlying: Common Stock · 365,853 shares

Expires not disclosed

F1 · derivative.exercise_price: The exercise price is $0.00001 per share.

F2 · derivative.exercise_date: The Pre-Funded Warrants have no expiration date and are exercisable immediately. Notwithstanding the foregoing, Venrock Opportunities Fund, L.P. ("VOF") shall not be entitled to exercise the Pre-Funded Warrants to the extent that such exercise would cause the aggregate number of shares of Common Stock beneficially owned by VOF, its affiliates and any persons whose ownership would be aggregated with VOF's for purposes of Section 13(d) of the Securities Exchange Act to exceed 4.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise.

F2 · derivative.expiration_date: The Pre-Funded Warrants have no expiration date and are exercisable immediately. Notwithstanding the foregoing, Venrock Opportunities Fund, L.P. ("VOF") shall not be entitled to exercise the Pre-Funded Warrants to the extent that such exercise would cause the aggregate number of shares of Common Stock beneficially owned by VOF, its affiliates and any persons whose ownership would be aggregated with VOF's for purposes of Section 13(d) of the Securities Exchange Act to exceed 4.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise.

F3 · ownership.nature: Securities are held directly by VOF. Venrock Opportunities Management, LLC ("VO Management") is the general partner of VOF. The Reporting Person is a voting member of VO Management and expressly disclaims beneficial ownership over all shares held by VOF except to the extent of his indirect pecuniary interests therein.

SEC source: 0001104659-25-096792 · tm2527919-1_4seq1.xml · derivative · entry 3

Dambkowski Carl · CIK 0001983476 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 161,625

Underlying: Common Stock · 2,385 shares

Expires 2033-12-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer.

SEC source: 0001104659-25-096792 · tm2527919-1_4seq1.xml · nonDerivative · entry 2

Dambkowski Carl · CIK 0001983476 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 284,733

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024.

F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.33 to $40.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001104659-25-096792 · tm2527919-1_4seq1.xml · nonDerivative · entry 1

Dambkowski Carl · CIK 0001983476 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 289,843

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001104659-25-087939 · tm2525198-1_4seq1.xml · nonDerivative · entry 2

Dambkowski Carl · CIK 0001983476 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 233,548

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024.

F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.54 to $38.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001104659-25-087939 · tm2525198-1_4seq1.xml · nonDerivative · entry 1

Dambkowski Carl · CIK 0001983476 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 233,738

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024.

F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.39 to $38.37, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001104659-25-075801 · tm2522902-1_4seq1.xml · nonDerivative · entry 1

Dambkowski Carl · CIK 0001983476 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 236,273

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024.

SEC source: 0001104659-25-065888 · tm2519824-1_4seq1.xml · derivative · entry 5

Dambkowski Carl · CIK 0001983476 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 164,010

Underlying: Common Stock · 7,365 shares

Expires 2033-12-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer.

SEC source: 0001104659-25-065888 · tm2519824-1_4seq1.xml · nonDerivative · entry 4

Dambkowski Carl · CIK 0001983476 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 238,998

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024.

F4 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.16 to $46.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001104659-25-065888 · tm2519824-1_4seq1.xml · nonDerivative · entry 3

Dambkowski Carl · CIK 0001983476 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 239,744

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024.

F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.14 to $46.11, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001104659-25-065888 · tm2519824-1_4seq1.xml · nonDerivative · entry 2

Dambkowski Carl · CIK 0001983476 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 242,679

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024.

F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $44.12 to $45.11, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001104659-25-065888 · tm2519824-1_4seq1.xml · nonDerivative · entry 1

Dambkowski Carl · CIK 0001983476 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 249,088

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001104659-25-061277 · tm2518364-6_4seq1.xml · derivative · entry 1

Shah Nimish P · CIK 0001698082 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,461

Underlying: Common Stock · 14,461 shares

Expires 2035-06-17

F1 · derivative.exercise_date: This option represents the right to purchase 14,461 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date.

F2 · ownership.direct: Under an agreement between the Reporting Person and VR Management, LLC (the "Management Company"), the Reporting Person is deemed to hold the reported option and the shares underlying the option for the sole benefit of the Management Company and must exercise the reported option solely upon the direction of the Management Company, which is entitled to the shares underlying the option. The Management Company may be deemed the indirect beneficial owner of the shares underlying the option, and the Reporting Person may be deemed the indirect beneficial owner of the reported shares underlying the option through his interest in the Management Company. The Reporting Person disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-061275 · tm2518364-7_4seq1.xml · derivative · entry 1

JONES WILLIAM A JR · CIK 0001373097 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,461

Underlying: Common Stock · 14,461 shares

Expires 2035-06-17

F1 · derivative.exercise_date: This option represents the right to purchase 14,461 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date.

SEC source: 0001104659-25-061278 · tm2518364-2_4seq1.xml · derivative · entry 2

Fairmount Funds Management LLC · CIK 0001802528 · Director

Kiselak Tomas · CIK 0001830177 · Director

Harwin Peter Evan · CIK 0001663607 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By: Tomas Kiselak

Disclosed balance after: 14,461

Underlying: Common Stock · 14,461 shares

Expires 2035-06-17

F1 · derivative.exercise_date: This option represents the right to purchase 14,461 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date.

F3 · ownership.direct: Under Mr. Kiselak's arrangement with Fairmount, Mr. Kiselak holds the option for one or more Fairmount Funds. Mr. Kiselak is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaims beneficial ownership of the option and underlying common stock. Fairmount disclaims beneficial ownership of any of the reported securities, except to the extent of its pecuniary interest therein.

SEC source: 0001104659-25-061278 · tm2518364-2_4seq1.xml · derivative · entry 1

Fairmount Funds Management LLC · CIK 0001802528 · Director

Kiselak Tomas · CIK 0001830177 · Director

Harwin Peter Evan · CIK 0001663607 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By: Peter Harwin

Disclosed balance after: 14,461

Underlying: Common Stock · 14,461 shares

Expires 2035-06-17

F1 · derivative.exercise_date: This option represents the right to purchase 14,461 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date.

F2 · ownership.direct: Under Mr. Harwin's arrangement with Fairmount Funds Management LLC ('Fairmount'), Mr. Harwin holds the option for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). Mr. Harwin is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Harwin therefore disclaims beneficial ownership of the option and underlying common stock. Fairmount disclaims beneficial ownership of any of the reported securities, except to the extent of its pecuniary interest therein.

SEC source: 0001104659-25-061276 · tm2518364-5_4seq1.xml · derivative · entry 1

McKenna Mark C. · CIK 0001749623 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,461

Underlying: Common Stock · 14,461 shares

Expires 2035-06-17

F1 · derivative.exercise_date: This option represents the right to purchase 14,461 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date.

SEC source: 0001104659-25-061273 · tm2518364-3_4seq1.xml · derivative · entry 1

Fox Jennifer A. · CIK 0001841557 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,461

Underlying: Common Stock · 14,461 shares

Expires 2035-06-17

F1 · derivative.exercise_date: This option represents the right to purchase 14,461 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date.

SEC source: 0001104659-25-061274 · tm2518364-1_4seq1.xml · derivative · entry 1

Gottesdiener Andrew · CIK 0001972292 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,461

Underlying: Common Stock · 14,461 shares

Expires 2035-06-17

F1 · derivative.exercise_date: This option represents the right to purchase 14,461 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date.

F2 · ownership.direct: Under an agreement between the Reporting Person and VR Management, LLC (the "Management Company"), the Reporting Person is deemed to hold the reported option and the shares underlying the option for the sole benefit of the Management Company and must exercise the reported option solely upon the direction of the Management Company, which is entitled to the shares underlying the option. The Management Company may be deemed the indirect beneficial owner of the shares underlying the option, and the Reporting Person may be deemed the indirect beneficial owner of the reported shares underlying the option through his interest in the Management Company. The Reporting Person disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-061272 · tm2518364-4_4seq1.xml · derivative · entry 1

Bollinger Lisa · CIK 0002024557 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,461

Underlying: Common Stock · 14,461 shares

Expires 2035-06-17

F1 · derivative.exercise_date: This option represents the right to purchase 14,461 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date.

SEC source: 0001104659-25-057468 · tm2517306-1_4seq1.xml · nonDerivative · entry 1

Dambkowski Carl · CIK 0001983476 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 241,723

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024.

SEC source: 0001104659-25-046896 · tm2514565-1_4seq1.xml · nonDerivative · entry 1

Dambkowski Carl · CIK 0001983476 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 244,448

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024.

F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.23 to $36.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001104659-25-032308 · tm2511489-1_4seq1.xml · nonDerivative · entry 3

Dambkowski Carl · CIK 0001983476 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 247,173

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024.

F4 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.34 to $37.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001104659-25-032308 · tm2511489-1_4seq1.xml · nonDerivative · entry 2

Dambkowski Carl · CIK 0001983476 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 248,062

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024.

F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.32 to $37.26, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001104659-25-032308 · tm2511489-1_4seq1.xml · nonDerivative · entry 1

Dambkowski Carl · CIK 0001983476 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 248,562

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024.

F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.09 to $36.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001104659-25-021861 · tm258443-2_4seq1.xml · nonDerivative · entry 2

HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,292,987

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2023.

F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.52 to $30.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001104659-25-021861 · tm258443-2_4seq1.xml · nonDerivative · entry 1

HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,295,661

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2023.

F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.49 to $30.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001104659-25-021862 · tm258443-1_4seq1.xml · nonDerivative · entry 1

Dambkowski Carl · CIK 0001983476 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 251,033

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024.

SEC source: 0001104659-25-010642 · tm255633-1_4seq1.xml · nonDerivative · entry 1

HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,302,987

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2023.

F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.30 to $40.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001104659-25-010645 · tm255633-2_4seq1.xml · derivative · entry 3

Dambkowski Carl · CIK 0001983476 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 171,375

Underlying: Common Stock · 795 shares

Expires 2033-12-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer.

SEC source: 0001104659-25-010645 · tm255633-2_4seq1.xml · nonDerivative · entry 2

Dambkowski Carl · CIK 0001983476 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 252,623

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 21, 2024.

F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.42 to $41.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001104659-25-010645 · tm255633-2_4seq1.xml · nonDerivative · entry 1

Dambkowski Carl · CIK 0001983476 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 256,143

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001104659-25-008235 · tm255141-1_4seq1.xml · derivative · entry 2

HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 390,012

Underlying: Common Stock · 8,500 shares

Expires 2033-12-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This option represents the right to purchase 398,512 shares of the Issuer's common stock, one quarter of which vested on December 18, 2024, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer.

SEC source: 0001104659-25-008235 · tm255141-1_4seq1.xml · nonDerivative · entry 1

HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,317,987

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001104659-25-002688 · tm252859-1_4seq1.xml · nonDerivative · entry 2

HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,309,487

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2023.

F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $49.35 to $49.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range

SEC source: 0001104659-25-002688 · tm252859-1_4seq1.xml · nonDerivative · entry 1

HENDERSON MICHAEL THOMAS · CIK 0001779990 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,312,355

F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2023.

F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $48.20 to $49.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001104659-25-000956 · tm251928-1_4seq1.xml · derivative · entry 5

Dambkowski Carl · CIK 0001983476 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 172,170

Underlying: Common Stock · 1,360 shares

Expires 2033-12-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: This option represents the right to purchase 175,345 shares of the Issuer's common stock, which will vest in forty-eight equal monthly installments through December 18, 2027, subject to the Reporting Person's continued service to the Issuer.